Please login to the form below

Not currently logged in
Email:
Password:

Orexo and Hospira sign Rapinyl distribution agreement

Orexo and Hospira sign a distribution agreement which grants Hospira exclusive rights to market and sell Rapinyl break-through cancer pain treatment in the Asia-Pacific region

Sweden-based pharmaceutical company Orexo and specialty medication delivery company Hospira have signed a distribution agreement which grants Hospira exclusive rights to market and sell Rapinyl (fast-dissolve fentanyl), Orexo's break-through cancer pain treatment.

The contract with Hospira covers distribution rights in Asia Pacific markets including Australia and New Zealand. Hospira will also be responsible for regulatory approval in these markets.

The market rights for Rapinyl were licensed to Kyowa Hakko Kogyo for the Japanese market in 2003. For North America, Orexo licensed the drug to Endo Pharmaceuticals in 2004 and to ProStrakan for the EU in 2005. In 2006, a distribution agreement was signed with Hungarian distributor Gedeon Richter for the CIS, Bulgaria and Romania.

Rapinyl was developed using Orexo's proprietary sublingual tablet technology, where a rapidly dissolving tablet is placed under the tongue and the active substance is absorbed by the mucous membrane.

Zsolt Lavotha, CEO of Orexo, said: "Hospira has a strong market position in cancer treatment, and the company has a well-established distribution network in the Asia Pacific region. We believe that Hospira will be effectively commercialising Rapinyl in all the markets in the territory. For Orexo, distributor agreements are important source for generating additional profitability from Rapinyl on a global basis."

Tim Oldham, president of Hospira Asia-Pacific, said: "The Asia Pacific market is growing rapidly, both in terms of patients and access, and this new partnership with Orexo will help our companies improve the life of patients and the effectiveness of their caregivers in the region."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics